Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.81 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.56 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.48 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | ATF4 | P18848 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2211794 | 0.91 | HRH3 (0.98) | HRH3SCN9ASCN10ASCN7AKCNH2 | |
| SCHEMBL2210268 | 0.90 | HRH3 (1.00) | HRH3SCN9ASCN10ASCN7AKCNH2 | |
| SCHEMBL2208108 | 0.86 | HRH3 (0.85) | HRH3SCN9A | |
| SCHEMBL1380318 | 0.86 | HRH3 (0.84) | HRH3SCN9AATF4 | |
| SCHEMBL2206434 | 0.85 | HRH3 (0.83) | HRH3SCN9ASCN10ASCN7AKCNH2 | |
| SCHEMBL4490173 | 0.85 | HRH3 (0.81) | HRH3KCNH2 | |
| SCHEMBL2210587 | 0.85 | HRH3 (1.00) | HRH3SCN9A | |
| SCHEMBL2208663 | 0.83 | HRH3 (0.83) | HRH3SCN9A | |
| SCHEMBL2208762 | 0.83 | HRH3 (0.78) | HRH3SCN9AATF4 | |
| SCHEMBL2208642 | 0.82 | HRH3 (0.78) | HRH3SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805166-B1 | QUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-07-27 | — | — | EP | claimed |
| US-7534891-B2 | Quinoline derivatives as H3R inverse agonists | HOFFMAN-LA ROCHE INC. (US) | 2009-05-19 | — | — | US | claimed |
| US-20060084679-A1 | Quinoline derivatives as H3R inverse agonists | HOFFMANN-LA ROCHE INC. | 2006-04-20 | — | — | US | claimed |
| EP-1805166-B1 | QUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-7534891-B2 | Quinoline derivatives as H3R inverse agonists | HOFFMAN-LA ROCHE INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20060084679-A1 | Quinoline derivatives as H3R inverse agonists | HOFFMANN-LA ROCHE INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084679-A1 | Quinoline derivatives as H3R inverse agonists | HRH3, HRH4, HRH1 | HRH3 1/4885SCN9A 690/4885SCN10A 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.